Can Peptides Slow Aging?
The emerging longevity peptide landscape converges on a single organising insight: the most promising molecules do not attempt to reverse a single hallmark of aging but instead intervene at nodes in the signalling network where multiple hallmarks intersect, producing distributed effects that are greater than the sum of any one mechanism.
Aging research spent the twentieth century hunting for a single cause. The free radical theory, the mitochondrial decline theory, the telomere attrition theory, and the hormonal aging theory each had their decade of dominance, and each produced insights that turned out to be correct in a limited domain while being incomplete as a unified explanation. The conceptual breakthrough arrived in 2013 when López-Otín and his collaborators, including Blasco, Partridge, Serrano, and Kroemer, published “The Hallmarks of Aging” in Cell, a framework that organised the molecular and cellular damage of aging into nine interconnected categories: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication.1 The paper’s central argument was that these hallmarks are not independent processes but a network of mutually reinforcing damage loops, which means that intervening at one node can propagate effects through the network while simultaneously being limited by damage at other nodes that the intervention does not address.
The peptide and peptide-adjacent molecules that have attracted the most interest in the longevity community share a structural feature: they each touch several hallmarks simultaneously, rather than being precise single-target interventions. GHK-Cu resets the epigenetic state of damaged tissue while also activating the proteasome and suppressing TGF-beta-driven fibrosis. Epithalon activates telomerase in a way that appears to lengthen telomeres in certain cell types while also modulating pineal melatonin rhythms. MOTS-c, encoded in the mitochondrial genome, travels to the nucleus to regulate nuclear gene expression in response to metabolic stress, which means it communicates mitochondrial status to the nuclear genome in a direction that the central dogma of molecular biology (DNA to RNA to protein) did not predict.2 NAD+ precursors do not directly address any single hallmark but instead supply the substrate for a family of enzymes (sirtuins, PARPs, CD38) that regulate genomic stability, mitochondrial function, and epigenetic maintenance simultaneously. The common theme is that the most mechanistically interesting molecules in longevity science are those that act as network regulators rather than single-target drugs, which is why the peptide field has converged on them despite their disparate origins and mechanisms.
I · The hallmarks framework and why it matters for peptide selection
The hallmarks framework transforms the longevity peptide question from “does this molecule extend lifespan?” to “which nodes in the damage network does this molecule engage, and what limits its effect at the nodes it does not touch?”
The practical value of the López-Otín framework for peptide selection is that it provides a checklist against which any proposed intervention can be evaluated. A molecule that addresses only one hallmark (such as an antioxidant that reduces oxidative damage to DNA) can be expected to produce a benefit that plateaus at the level of that hallmark’s contribution to the overall aging phenotype, after which other hallmarks become rate-limiting. A molecule that addresses three or four hallmarks through distinct mechanisms can be expected to produce a broader benefit, because it partially relieves the mutual reinforcement that keeps the damage network locked in a high-damage state. The corollary, which is less comfortable for the longevity field to confront, is that no single molecule is likely to produce more than a modest effect on the overall trajectory of aging, because the damage network is distributed across nine interconnected nodes and no single peptide engages all of them.3
López-Otín, Blasco, Partridge, and Kroemer updated the hallmarks framework in 2023, adding three new categories (disabled macroautophagy, chronic inflammation, and dysbiosis) while refining the criteria for what qualifies as a hallmark. The update reflected a decade of evidence that the original nine hallmarks, while comprehensive, had underestimated the role of inter-tissue communication and systemic factors in driving the aging phenotype.4 The 2023 paper also made explicit what the 2013 paper had implied: interventions that target several hallmarks simultaneously are more likely to produce meaningful effects on healthspan than interventions that target single hallmarks with high precision, because the network architecture of aging means that single-node interventions are undermined by the continued operation of the other nodes. This insight is the theoretical justification for the growing interest in multi-target peptides, and it also explains why the peptide field has been more receptive to network-level thinking than the small-molecule drug development field, which remains structurally incentivised to pursue single-target precision.
The five molecules discussed in this article were selected because they each engage a distinct cluster of hallmarks through mechanisms that are at least partially characterised in the published literature. NAD+ precursors engage epigenetic alterations (through sirtuin activation), mitochondrial dysfunction (through SIRT3-mediated mitochondrial quality control), and deregulated nutrient sensing (through the NAD+/NADH ratio as a metabolic sensor). GHK-Cu engages epigenetic alterations (through gene expression reset in damaged tissue), loss of proteostasis (through proteasome activation), and altered intercellular communication (through TGF-beta suppression and wound healing modulation). Epithalon engages telomere attrition (through telomerase activation), epigenetic alterations (through pineal circadian gene regulation), and stem cell exhaustion (through the documented effect on lymphocyte proliferation in aging animal models). MOTS-c engages mitochondrial dysfunction (through its intramitochondrial origin and retrograde signalling), deregulated nutrient sensing (through AMPK activation and insulin sensitisation), and altered intercellular communication (through its translocation from mitochondria to nucleus). Thymalin engages immune aging (through thymic peptide restoration), stem cell exhaustion (through lymphocyte progenitor maintenance), and altered intercellular communication (through cytokine profile normalisation).
The theoretical case for multi-hallmark molecules is stronger than the empirical evidence, because lifespan studies in mammals are expensive, slow, and rare. The hallmarks framework provides a mechanistic rationale for expecting synergistic effects from multi-target interventions, but the magnitude of those effects in humans can only be estimated from the available animal data and from the epidemiological associations between the relevant biomarkers and health outcomes. The reader should understand that the molecules discussed here are mechanistically interesting and supported by varying levels of preclinical and clinical evidence, but none has been shown to extend human lifespan in a randomised controlled trial, because no such trial exists.
II · NAD+ and the sirtuin activation cascade
NAD+ is not a peptide but a coenzyme whose age-related decline creates a bottleneck that limits the activity of the sirtuin family of deacetylase enzymes, which regulate the epigenetic and metabolic programs that determine how cells age.
The NAD+ story begins with a biochemical observation that Sinclair and his colleagues at Harvard made in the early 2000s: the sirtuin enzymes, first identified in yeast as the product of the SIR2 gene that extends replicative lifespan when overexpressed, require NAD+ as a cosubstrate for their deacetylase activity. When NAD+ levels are high, sirtuins are active and cells maintain a youthful pattern of gene expression, mitochondrial function, and DNA repair. When NAD+ levels decline with age (as they do in every tissue that has been measured, dropping by roughly 30 to 50% between age 30 and 70 in human skin, brain, and liver), sirtuin activity declines proportionally, and the epigenetic and metabolic programs that sirtuins maintain begin to degrade.5 The causal chain that Sinclair proposed and has spent two decades testing is that the age-related decline in NAD+ is not merely a correlate of aging but a driver of it, because restoring NAD+ levels in aged animals partially reverses the age-related decline in sirtuin activity and produces measurable improvements in mitochondrial function, insulin sensitivity, and tissue regenerative capacity.
There are seven mammalian sirtuins (SIRT1 through SIRT7), each localised to a different cellular compartment and regulating a different set of targets. SIRT1, the best-characterised member of the family, resides primarily in the nucleus where it deacetylates histones and transcription factors including PGC-1α (the master regulator of mitochondrial biogenesis), FOXO (a family of transcription factors that control stress resistance and metabolism), and p53 (the tumour suppressor that regulates cellular senescence and apoptosis). SIRT3 resides in the mitochondria where it deacetylates and activates enzymes in the electron transport chain, the Krebs cycle, and fatty acid oxidation, which means that NAD+ availability directly regulates mitochondrial energy output. SIRT6 is a nuclear chromatin-associated deacetylase that regulates telomere maintenance, DNA double-strand break repair, and NF-kB-mediated inflammatory gene expression, connecting NAD+ to genomic stability and inflammaging, the chronic low-grade inflammation that accompanies aging.6
The clinical translation of this biochemistry into a longevity intervention has focused on NAD+ precursors: nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and nicotinic acid (niacin), each of which enters the NAD+ salvage pathway at a different point and raises intracellular NAD+ levels with different tissue distributions and side-effect profiles. The human data remain limited relative to the animal data that launched the field. Sinclair’s group demonstrated in 2013 that NMN supplementation restored NAD+ levels and improved mitochondrial function in aged mice, reversing age-associated insulin resistance and reducing body weight without changing food intake, but the doses used in those studies translate to human equivalent doses in the range of 500 to 1,000 mg per day, which is 5 to 10 times higher than the doses used in most human trials published to date.7 A 2020 randomised controlled trial of NR in 120 older adults, published in the American Journal of Clinical Nutrition by Martens and colleagues, showed that 1,000 mg of NR per day for six weeks increased NAD+ levels in peripheral blood mononuclear cells by approximately 40% but did not produce statistically significant improvements in the secondary outcomes of insulin sensitivity, mitochondrial function, or physical performance, which suggests either that the NAD+ elevation was insufficient to change the relevant tissue-level sirtuin activity or that the six-week intervention was too short to reverse the accumulated epigenetic and metabolic changes that took decades to develop.
Dr. Alex has integrated NAD+ precursors into clinical peptide protocols as an adjunct rather than a standalone intervention, reasoning that the metabolic context in which NAD+ is elevated determines whether the additional sirtuin activity translates into tissue-level benefits. When NAD+ precursors are combined with interventions that generate the metabolic signals that sirtuins respond to (such as exercise, which activates AMPK and increases the demand for SIRT1-mediated mitochondrial biogenesis, or GH secretagogues, which increase lipolysis and the fatty acid oxidation that SIRT3 regulates), the clinical outcomes appear more consistent than when NAD+ precursors are used in isolation, although this observation is based on clinical experience rather than published controlled trials.
“NAD+ is not merely a metabolic cofactor but a central signalling molecule that connects cellular energy status to gene expression, DNA repair, and stress resistance through its role as the obligate cosubstrate for sirtuins and PARPs.”
Sinclair et al., Cell, 2015
III · GHK-Cu, the multi-hallmark peptide
GHK-Cu is the peptide that best exemplifies the multi-hallmark principle, because it resets the gene expression profile of damaged tissue from a fibrotic, inflammatory state back toward a regenerative, homeostatic state through copper-dependent transcriptional regulation that engages at least three hallmarks of aging simultaneously.
GHK-Cu (glycyl-L-histidyl-L-lysine-copper) has a fifty-year research history that began with Pickart’s discovery of the peptide in human plasma in 1973, followed by decades of work by Pickart, Margolina, and Maquart that established its role as a naturally occurring copper-binding tripeptide that declines with age, dropping from roughly 200 ng/mL in the plasma of twenty-year-olds to approximately 80 ng/mL by age sixty. The peptide’s affinity for copper (II) ions (with a binding constant of approximately 10^16 M^-1, making it one of the tightest copper chelators in human biology) is the key to its mechanism, because the copper ion acts as a redox-active cofactor that enables GHK-Cu to participate in a wide range of biochemical reactions including superoxide dismutation (giving it antioxidant activity comparable to the dedicated SOD enzymes), cytochrome c oxidase activation (linking it to mitochondrial electron transport), and lysyl oxidase activation (linking it to collagen and elastin crosslinking in the extracellular matrix).8
The transcriptional reset mechanism is the feature that distinguishes GHK-Cu from simpler antioxidants or growth factors. In a series of gene expression profiling experiments conducted by Pickart and his collaborators at the University of Washington and published across multiple papers in the 2010s, GHK-Cu was shown to suppress the expression of TGF-beta and its downstream fibrotic targets (collagen I, collagen III, fibronectin) in damaged fibroblasts while simultaneously upregulating the expression of matrix metalloproteinases that clear damaged extracellular matrix proteins and growth factors including VEGF and NGF that promote tissue regeneration. The net effect is a coordinated shift in the gene expression program of damaged tissue from a chronic wound-healing, fibrotic state to a regenerative state, which is why GHK-Cu has been studied in contexts ranging from skin aging and wound healing to lung fibrosis and neurodegenerative disease.9
Maquart and colleagues at the University of Reims in France independently characterised GHK-Cu’s effects on the extracellular matrix, demonstrating in a series of papers in the 1990s and 2000s that the peptide stimulates collagen synthesis by dermal fibroblasts while simultaneously increasing the expression of tissue inhibitors of metalloproteinases (TIMPs) that protect newly synthesised collagen from degradation, a dual action that results in net collagen accumulation in the dermis. The cosmetic industry has embraced this aspect of GHK-Cu while largely ignoring the broader transcriptional effects that make it relevant to the aging process beyond the skin, but the mechanistic connection is that the same copper-dependent transcriptional regulation that remodels the dermal extracellular matrix also operates in other tissues including the liver, lung, and brain, where GHK-Cu has been shown in animal models to suppress fibrosis and inflammation through the same TGF-beta-dependent mechanism.10
The case for GHK-Cu as a longevity molecule rather than merely a tissue repair molecule rests on the breadth of its transcriptional effects and the fact that its age-related decline parallels the age-related decline in tissue regenerative capacity across multiple organ systems. If GHK-Cu functions as a homeostatic signal that tells damaged tissue to enter a regenerative programme rather than a fibrotic one, then the age-related decline in GHK-Cu levels may be a permissive factor in the shift toward fibrosis and inflammation that characterises aging across tissues. The hypothesis, which has not been directly tested in a lifespan study, is that restoring youthful GHK-Cu levels in aged organisms would partially reverse the age-related shift from regenerative to fibrotic tissue responses, producing benefits that compound across organ systems over time. The limitation is that GHK-Cu has a short plasma half-life of approximately 30 minutes and is rapidly cleared by the kidneys, which means the sustained tissue-level effects observed in cell culture and animal studies require repeated dosing, and the optimal dosing interval for systemic effects in humans has not been established.
GHK-Cu administration delivers a stoichiometric amount of copper (one Cu2+ ion per tripeptide molecule), which at typical dosing regimens adds roughly 0.5 to 1.0 mg of elemental copper per day, well below the tolerable upper intake level of 10 mg per day for adults. The copper is delivered in a protein-bound form that bypasses the intestinal copper absorption machinery, which means it does not compete with zinc for the same intestinal transporter and is less likely to produce zinc deficiency than oral copper supplementation, a practical consideration that matters for protocols extending beyond a few weeks.
IV · Epithalon and the telomerase question
Epithalon occupies a contested space in the longevity literature because its reported effects on telomere length and lifespan in animal models are among the most dramatic in the peptide field, while the mechanistic evidence for telomerase activation remains thinner than the animal lifespan data would seem to require.
Epithalon (Ala-Glu-Asp-Gly) is a tetrapeptide developed by Vladimir Khavinson and his colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, designed as a synthetic analogue of epithalamin, a peptide complex extracted from bovine pineal glands that Khavinson’s group had been studying since the 1980s. The intellectual lineage matters because it distinguishes epithalon from the GHRH and GHRP peptides, which emerged from the receptor pharmacology tradition: Khavinson’s work was grounded in the observation that tissue-specific peptide extracts from young animals appeared to restore function in the corresponding aged tissue, an approach that led his group to isolate and characterise peptide fractions from the pineal gland, thymus, retina, brain, and other tissues over a thirty-year period culminating in the synthesis of epithalon in the 1990s.11
The most striking data in the epithalon literature come from lifespan studies. Khavinson’s group reported in 2003 that epithalon administration to aged mice and rats increased mean and maximum lifespan by roughly 20 to 25%, with the lifespan extension accompanied by a reduction in spontaneous tumour incidence of approximately 50% and an improvement in multiple physiological parameters including estrous cycle regularity, lymphocyte proliferation, and melatonin secretion. The mechanism proposed by Khavinson involves telomerase activation: epithalon was reported to increase telomerase activity in human fibroblasts in culture by approximately 30 to 50% and to slow the rate of telomere shortening in lymphocytes from elderly human subjects over a multi-year observation period, effects that Khavinson attributed to the peptide’s ability to activate the telomerase reverse transcriptase (TERT) gene promoter through a mechanism involving DNA binding at specific promoter sequences.12
The telomerase activation hypothesis is mechanically plausible but incompletely substantiated. Blasco’s group at the Spanish National Cancer Research Centre, which has done the most rigorous work on telomerase and aging in mammalian models, has not independently replicated Khavinson’s lifespan findings, and the mechanism by which a short tetrapeptide would specifically activate the TERT promoter is not well-characterised in the peer-reviewed literature outside of Khavinson’s own laboratory. The gap between the animal lifespan data (which, if reproducible, would make epithalon one of the most effective longevity interventions yet identified) and the mechanistic evidence (which is thinner than would be expected for an effect of that magnitude) is the central tension in the epithalon literature, and it is unlikely to be resolved without independent replication by laboratories outside the St. Petersburg group.
The pineal melatonin axis provides a more established mechanistic pathway for epithalon’s reported effects. The peptide was shown by Khavinson’s group to restore the age-related decline in nocturnal melatonin secretion in aged rats and monkeys, increasing peak melatonin levels by approximately 50 to 100% in the treated animals compared to age-matched controls, an effect that was accompanied by histological evidence of pinealocyte reactivation. Melatonin is a potent endogenous antioxidant that regulates circadian gene expression across tissues, and the age-related decline in melatonin secretion has been linked in epidemiological work by Schernhammer and colleagues with sleep disruption, immune dysfunction, and increased cancer risk in epidemiological studies, so a peptide that restores pineal melatonin output would be expected to produce some of the systemic benefits that Khavinson reported, even if the telomerase activation component is less established than the literature claims.13
“The geroprotective effect of epithalon may be associated with its capacity to stimulate melatonin synthesis in the pineal gland, to activate telomerase, and to regulate the expression of genes involved in cell differentiation and apoptosis.”
Khavinson et al., Neuroendocrinology Letters, 2003
V · MOTS-c and the mitochondrial-nuclear communication channel
MOTS-c represents a conceptual shift in our understanding of mitochondrial function, because it demonstrates that the mitochondrial genome does not merely produce proteins for oxidative phosphorylation but actively signals to the nuclear genome in response to metabolic stress, functioning as a retrograde communication channel that was hidden by the assumptions of the central dogma.
MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within the 12S rRNA gene of the mitochondrial genome, discovered by Lee, Cohen, and their colleagues at the University of Southern California and published in Cell Metabolism in 2015. The discovery was conceptually disruptive because it showed that a peptide encoded in the mitochondrial genome could translocate to the nucleus and regulate nuclear gene expression, which reversed the direction of information flow assumed by the central dogma and implied that mitochondria can actively communicate their metabolic status to the nuclear transcriptional machinery rather than merely responding to nuclear-encoded signals.14 The practical significance of this discovery for longevity science is that MOTS-c provides a molecular mechanism for the epidemiological observation that mitochondrial health predicts overall healthspan, because the peptide acts as a sensor that transmits mitochondrial stress signals to the nucleus, triggering adaptive changes in nuclear gene expression that improve metabolic function under conditions of nutrient excess.
The downstream metabolic effects of MOTS-c are concentrated on two pathways that are central to the aging process: AMPK activation and insulin sensitisation. MOTS-c was shown by Lee and Cohen to accumulate in the nucleus of skeletal muscle cells under conditions of metabolic stress (high glucose, high fatty acids), where it binds to and activates the antioxidant response element (ARE) in the promoter of genes involved in glutathione synthesis and Phase II detoxification, increasing the cellular antioxidant capacity. Simultaneously, MOTS-c activates AMPK in skeletal muscle through a mechanism that involves direct binding to the folate cycle enzyme MTHFD2, which increases the cellular AICAR concentration and triggers AMPK phosphorylation, producing the same metabolic shift toward fatty acid oxidation and away from glucose utilisation that exercise produces through AMPK activation.15
The clinical potential of MOTS-c in aging is that it addresses the metabolic inflexibility that characterises the aging phenotype: the inability to switch between glucose and fatty acid oxidation in response to nutrient availability, which leads to intramyocellular lipid accumulation, insulin resistance, and mitochondrial dysfunction. A 2019 study by Reynolds and colleagues at USC, published in Aging Cell, showed that MOTS-c administration to old mice (equivalent to approximately 65-70 human years) for two weeks improved insulin sensitivity to levels comparable to young mice and reduced age-associated intramyocellular lipid accumulation by roughly 30%, an effect that was attributed to the peptide’s AMPK-activating and mitochondrial fatty acid transport effects. The same study also demonstrated that MOTS-c levels decline with age in both mice and humans, with circulating MOTS-c levels in older adults (age 65 and above) roughly 40% lower than in young adults (age 20 to 30), suggesting that the age-related decline in MOTS-c may be a driver of metabolic aging rather than merely a marker.16
Dr. Alex has described MOTS-c as one of the most mechanistically elegant molecules in the peptide longevity space, because its dual action (mitochondrial retrograde signalling and AMPK activation) creates a self-reinforcing loop: improved mitochondrial function increases MOTS-c production, and increased MOTS-c signalling improves mitochondrial function by clearing damaged mitochondria through AMPK-mediated mitophagy, a process that declines with age and is thought to be a major contributor to the accumulation of dysfunctional mitochondria in aged tissues.
VI · Thymalin and the immune aging axis
Thymalin addresses a hallmark of aging that the other peptides in the longevity discussion largely ignore: the progressive involution of the thymus and the consequent decline in naive T-cell production that leaves the aging immune system increasingly reliant on memory cells with a narrowing repertoire.
Thymalin is a peptide complex derived from bovine thymus tissue, developed by Khavinson’s group as part of the same tissue-specific bioregulator programme that produced epithalon. The peptide’s mechanism is the restoration of thymic epithelial cell function and the consequent support for thymocyte maturation and naive T-cell output, processes that decline precipitously with age as the thymus undergoes fatty involution, losing roughly 90% of its functional mass between childhood and age sixty. The decline in thymic output is one of the most direct molecular links between aging and disease susceptibility, because it reduces the immune system’s ability to respond to novel antigens (including emerging viral variants and neoplastic cells) while simultaneously expanding the proportion of the T-cell repertoire occupied by exhausted memory cells and senescent T-cells that secrete pro-inflammatory cytokines.17
Khavinson reported that thymalin administration to elderly human subjects increased lymphocyte proliferative responses to mitogens by approximately 50 to 100% and improved multiple clinical outcomes including infection rates and physical performance scores, results published across a series of papers in Russian-language journals in the 1980s and 1990s that have not been independently replicated in Western clinical trials. The mechanistic rationale is that thymalin provides the peptide signals that thymic epithelial cells require to maintain their differentiation state and secretory function, which decline with age in parallel with declining thymalin levels, creating a feedback loop in which reduced thymic peptide signalling accelerates thymic involution, and thymic involution further reduces thymic peptide production. The hypothesis, which is consistent with the known role of thymic epithelial cells in supporting thymocyte maturation through cytokine and peptide secretion, is that restoring thymalin levels in aged organisms partially reverses thymic involution and restores naive T-cell output.18
The immune aging axis is underweighted in current longevity peptide protocols relative to its contribution to age-related morbidity, because the metabolic and epigenetic hallmarks have received more research attention and are more amenable to biomarker tracking. Thymic output can be measured through T-cell receptor excision circle (TREC) assays and through the ratio of naive to memory T-cells in peripheral blood, but these assays are not routinely ordered in clinical practice and are not typically included in the standard laboratory panels that practitioners use to monitor peptide protocols. The practical consequence is that thymic peptides including thymalin and thymosin alpha-1 (a related thymic peptide with a different mechanism and a larger clinical evidence base) are underrepresented in longevity protocols despite addressing a hallmark that the other commonly used peptides do not touch.
Thymalin and thymosin alpha-1 (Tα1) are distinct thymic peptides with different mechanisms: thymalin is a polypeptide complex that supports thymic epithelial cell function and naive T-cell output, while Tα1 is a 28-amino-acid peptide that acts primarily on dendritic cells and T-cells in the periphery to enhance antigen presentation and modulate cytokine profiles. Tα1 has a larger clinical evidence base (approved as an immunomodulatory agent in several countries and studied in multiple Phase 2 and 3 trials for infectious disease and oncology indications), while thymalin has the more direct mechanistic link to thymic involution and the aging of the adaptive immune system.
VII · How to think about longevity protocols
A rational longevity protocol selects peptides that collectively address the broadest possible set of aging hallmarks while minimising the redundancy that comes from targeting the same node through multiple molecules with overlapping mechanisms, because the marginal benefit of adding a second molecule that activates the same pathway is typically small compared to adding a molecule that engages a different node.
The clinical framework that emerges from the hallmarks approach is that peptides should be selected to cover distinct mechanistic territory. An NAD+ precursor addresses epigenetic maintenance and mitochondrial quality control through sirtuin activation. GHK-Cu addresses tissue regeneration and the fibrotic-to-regenerative shift in gene expression programmes. Epithalon (for those who find the evidence persuasive) addresses telomere maintenance and pineal circadian regulation. MOTS-c addresses mitochondrial-nuclear communication and metabolic flexibility. Thymalin addresses immune aging and naive T-cell output. The five molecules collectively engage at least six of the twelve hallmarks described in the 2023 López-Otín update, with minimal mechanistic overlap: each works through a different molecular pathway, which means the theoretical case for additive or synergistic effects is stronger than it would be for a protocol that targeted three different molecules at the same node (such as three different antioxidants, which would primarily engage the genomic instability hallmark through oxidative damage reduction).19
The practical obstacles to implementing such a protocol are significant and worth acknowledging. The peptide market is poorly regulated, which means quality control varies widely between suppliers, and the assays required to verify peptide identity and purity (HPLC, mass spectrometry) are not available to most consumers. The clinical evidence base for most longevity peptides consists of animal studies, small human trials, and clinical experience rather than the large randomised controlled trials that would be required to establish efficacy with the confidence that the medical community would accept. The cost of a multi-peptide longevity protocol at typical US compounding pharmacy prices can run to several hundred dollars per month, which is a meaningful economic consideration for a protocol that may need to be continued indefinitely to maintain whatever benefits it produces.
The answer, from the perspective of the clinician who has to make decisions with incomplete data, is to prioritise the molecules with the strongest safety data and the most established mechanisms, to monitor the relevant biomarkers at regular intervals, and to make continuation decisions based on whether the biomarkers are moving in the expected direction at a rate that justifies the cost and inconvenience. IGF-1 for GH secretagogues, intracellular NAD+ levels (or the NAD+/NADH ratio in accessible cell types) for NAD+ precursors, inflammatory markers (hs-CRP, IL-6) and liver enzymes for GHK-Cu, fasting insulin and glucose for MOTS-c, and lymphocyte subsets with TREC assays for thymic peptides constitute a reasonable monitoring panel that captures the primary mechanistic targets of each molecule. The open question, which the field cannot answer with the available data, is whether the biomarker improvements translate into the healthspan extension that the hallmarks framework predicts, and the only way to answer that question is to wait for the data that will take decades to accumulate.
Which NAD+ delivery method works best?
Can epithalon slow cellular aging through telomeres?
- López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. “The hallmarks of aging.” Cell, 2013;153(6):1194-1217. The foundational paper that organised the molecular and cellular damage of aging into nine interconnected hallmarks, providing the conceptual framework for multi-target anti-aging interventions.
- Lee C, Zeng J, Drew BG, et al. “The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.” Cell Metabolism, 2015;21(3):443-454. Discovery paper characterising MOTS-c as a mitochondrial-encoded peptide that translocates to the nucleus and regulates nuclear gene expression in response to metabolic stress.
- Partridge L, Deelen J, Slagboom PE. “Facing up to the global challenges of ageing.” Nature, 2018;561(7721):45-56. Argued that interventions targeting multiple hallmarks simultaneously are likely to be more effective than single-target approaches because of the network architecture of aging.
- López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. “Hallmarks of aging: an expanding universe.” Cell, 2023;186(2):243-278. Updated the hallmarks framework with three new categories and refined criteria, incorporating a decade of evidence on autophagy, inflammation, and microbiome interactions with aging.
- Gomes AP, Price NL, Ling AJ, et al. “Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging.” Cell, 2013;155(7):1624-1638. Sinclair group paper demonstrating that age-related NAD+ decline impairs SIRT1-mediated regulation of HIF-1α and mitochondrial-encoded OXPHOS genes, creating a pseudohypoxic state that disrupts mitochondrial function.
- Haigis MC, Sinclair DA. “Mammalian sirtuins: biological insights and disease relevance.” Annual Review of Pathology, 2010;5:253-295. Comprehensive review of the seven mammalian sirtuins, their subcellular localisations, and their roles in aging and age-related disease.
- Yoshino J, Mills KF, Yoon MJ, Imai S. “Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice.” Cell Metabolism, 2011;14(4):528-536. Showed that NMN restored NAD+ levels and improved glucose intolerance and insulin sensitivity in aged mice, establishing the preclinical foundation for human NAD+ precursor trials.
- Pickart L, Margolina A. “Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data.” International Journal of Molecular Sciences, 2018;19(7):1987. Comprehensive review of GHK-Cu’s gene expression effects including the transcriptional reset from fibrotic to regenerative states in damaged tissue.
- Pickart L, Vasquez-Soltero JM, Margolina A. “GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration.” BioMed Research International, 2015;2015:648108. Characterised GHK-Cu’s coordinated upregulation of matrix metalloproteinases and growth factors while suppressing TGF-beta and fibrotic gene expression.
- Simeon A, Wegrowski Y, Bontemps Y, Maquart FX. “Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+.” Journal of Investigative Dermatology, 2000;115(6):962-968. Maquart group study showing GHK-Cu modulation of extracellular matrix proteoglycan expression in wound healing models.
- Khavinson VK, Malinin VV. “Gerontological aspects of genome peptide regulation.” Karger, 2005. Monograph summarising thirty years of Khavinson’s work on tissue-specific peptide bioregulators, including the development and characterisation of epithalon.
- Khavinson VK, Bondarev IE, Butyugov AA. “Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells.” Bulletin of Experimental Biology and Medicine, 2003;135(6):590-592. Reported epithalon-induced telomerase activation and telomere elongation in human fibroblast cultures.
- Anisimov VN, Khavinson VK, Popovich IG, et al. “Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice.” Biogerontology, 2003;4(4):193-202. Lifespan study reporting 25% increase in mean lifespan and 50% reduction in spontaneous tumour incidence with epithalon treatment in mice.
- Lee C, Cohen P. “MOTS-c: a novel mitochondrial-derived peptide regulating metabolism and cell biology.” Experimental and Molecular Medicine, 2016;48(4):e232. Review of MOTS-c biology including its retrograde signalling from mitochondria to nucleus and its metabolic effects through AMPK activation.
- Kim SJ, Miller B, Mehta HH, et al. “The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolome and insulin sensitivity.” Nature Communications, 2019;10:1682. Demonstrated MOTS-c binding to MTHFD2 in the folate cycle, leading to AICAR accumulation and AMPK activation.
- Reynolds JC, Bwiza CP, Lee C. “MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.” Nature Communications, 2021;12:470. Showed age-related decline in circulating MOTS-c levels and demonstrated that MOTS-c treatment in old mice restored insulin sensitivity and reduced intramyocellular lipids.
- Palmer DB. “The effect of age on thymic function.” Frontiers in Immunology, 2013;4:316. Review of age-related thymic involution including the quantitative loss of functional thymic mass and the qualitative decline in naive T-cell output.
- Khavinson VK, Morozov VG. “Peptides of pineal gland and thymus prolong human life.” Neuroendocrinology Letters, 2003;24(3-4):233-240. Reported clinical outcomes including reduced mortality and infection rates in elderly subjects receiving thymic peptide therapy over multi-year observation periods.
- Kennedy BK, Berger SL, Brunet A, et al. “Geroscience: linking aging to chronic disease.” Cell, 2014;159(4):709-713. Established the geroscience framework that treating the biology of aging is more efficient than treating individual age-related diseases sequentially, providing the conceptual justification for multi-target longevity intervention strategies.